- Home
- INSW vs VRDN Comparison
INSW vs VRDN Comparison
Compare INSW & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INSW
- VRDN
- Stock Information
- Founded
- INSW 1999
- VRDN 2006
- Country
- INSW United States
- VRDN United States
- Employees
- INSW N/A
- VRDN N/A
- Industry
- INSW Semiconductors
- VRDN Medical Specialities
- Sector
- INSW Technology
- VRDN Health Care
- Exchange
- INSW Nasdaq
- VRDN Nasdaq
- Market Cap
- INSW 2.0B
- VRDN 1.6B
- IPO Year
- INSW N/A
- VRDN N/A
- Fundamental
- Price
- INSW $36.72
- VRDN $16.27
- Analyst Decision
- INSW Strong Buy
- VRDN Buy
- Analyst Count
- INSW 3
- VRDN 12
- Target Price
- INSW $60.67
- VRDN $36.44
- AVG Volume (30 Days)
- INSW 765.1K
- VRDN 941.3K
- Earning Date
- INSW 02-27-2025
- VRDN 03-04-2025
- Dividend Yield
- INSW 15.71%
- VRDN N/A
- EPS Growth
- INSW N/A
- VRDN N/A
- EPS
- INSW 10.33
- VRDN N/A
- Revenue
- INSW $1,007,734,000.00
- VRDN $302,000.00
- Revenue This Year
- INSW N/A
- VRDN $3.30
- Revenue Next Year
- INSW N/A
- VRDN N/A
- P/E Ratio
- INSW $3.56
- VRDN N/A
- Revenue Growth
- INSW N/A
- VRDN N/A
- 52 Week Low
- INSW $32.11
- VRDN $11.40
- 52 Week High
- INSW $65.94
- VRDN $27.20
- Technical
- Relative Strength Index (RSI)
- INSW 40.71
- VRDN 36.43
- Support Level
- INSW $37.81
- VRDN $15.62
- Resistance Level
- INSW $39.39
- VRDN $18.15
- Average True Range (ATR)
- INSW 1.39
- VRDN 0.91
- MACD
- INSW -0.31
- VRDN -0.20
- Stochastic Oscillator
- INSW 1.36
- VRDN 14.48
About INSW International Seaways Inc.
International Seaways Inc owns and operates a fleet of oceangoing vessels engaged in the transportation of crude oil and petroleum products. The company's vessel operations are organized into two segments: Crude Tankers and Product Carriers. The fleet consists of ULCC, VLCC, Suezmax, Aframax, and Panamax crude tankers, as well as LR1, LR2, and MR product carriers.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.